基因多态性和慢性乙型肝炎干扰素疗效的相关性

影响慢性乙型肝炎(CHB)IFN疗效的因素很多,宿主免疫遗传背景的差异是重要原因之一.最近关于基因多态性和CHB患者IFN疗效的相关性研究越来越多,此文就相关的研究进展进行了简要综述.     

拉米夫定和(或)阿德福韦酯治疗失代偿期乙型肝炎肝硬化3年疗效观察

目的 观察拉米夫定和(或)阿德福韦酯治疗失代偿期乙型肝炎肝硬化3年疗效.方法 收集乙型肝炎肝硬化失代偿期患者68例,分为抗病毒治疗组和对照组,观察入组患者的临床症状、体征、生化指标、HBV DNA和Child-Pugh分级等变化情况.结果 随访治疗中,治疗组6个月后ALT、ALB和HBV DNA水平均较对照组有明显改善,12个月后TBil和Child-Pugh评分较对照组有明显改善,差异具有统计学意义(P<0.05);治疗组和对照组36个月生存率分别为62.5%和36.1%,差异具有统计学意义(P< 0.05);36个月后治疗组和对照组肝细胞癌发生率分别为3.1%和8.3%,差异无统计学意义.结论 拉米夫定和(或)阿德福韦酯治疗失代偿期乙型肝炎肝硬化,能够改善患者肝功能,延缓疾病进展,提高生存率.     

基因多态性和慢性乙型肝炎干扰素疗效的相关性

影响慢性乙型肝炎(CHB)IFN疗效的因素很多,宿主免疫遗传背景的差异是重要原因之一.最近关于基因多态性和CHB患者IFN疗效的相关性研究越来越多,此文就相关的研究进展进行了简要综述.     

程序性细胞凋亡基因单核苷酸多态性与慢性乙型肝炎患者干扰素早期病毒学应答的相关性

Objective To investigate the relationship between the single nucleotide polymorphisms (SNP) of programmed cell death-1 (PD-1) gene and early virologic response of interferon-α (IFN-α) in patients with chronic hepatitis B (CHB). Methods A total of 135 CHB patients were prospectively enrolled in this study. SNP of PD-1.1 and PD-1.2 genes were examined by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) in these patients.Then its relationship with early virologic response to IFN-α treatment was analyzed. The data were analyzed by x2 test. Results Among the 135 patients, 33 (24.4%) achieved early virologic response to IFN-α. There were 35, 77, and 23 patients with AA, AG, GG genotgpe of PD-1.1. The early virologic response was achived in 5(14.3%), 25(32.5%) and 3(13.0%) among patients with AA,AG, GG genotypes of PD-1.1, respectively. There were statistically different (x2 = 6. 258, P =0. 044). The subjects with AG genotype showed higher response rate than those with AA or GG genotypes (x2 = 6. 246, P= 0. 012). However, the early virologic response rates were not significant different among subjects with AA, AG or GG genotype of PD-1. 2 ( x2= 3.957, P= 0. 138).Conclusion SNP of PD-1.1 gene may be used as a marker to predict the early virologic response to IFN-α treatment in Chinese CHB patients.     

血液透析患者中隐匿性乙型肝炎病毒感染的分子流行病学分析

血清HBsAg阴性,而血清或肝脏组织HBV DNA阳性被定义为隐匿性HBV感染.透析患者其自身免疫功能低下,且长期反复接受动静脉穿刺等原因,致其成为HBV感染的高危人群.在欧美地区的医疗机构里,透析单元中HBV的传播仍远大于内、外科病房及门诊,其HBsAg阴性的维持性血液透析患者隐匿性HBV感染的发生率为0.9%～12.4%[1-2].而国内鲜见相关报道.